Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.


Clinical Trial Description

This is a Phase III, multicenter, double-masked, randomized, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 1.0% ophthalmic suspension versus placebo in subjects who require treatment of postoperative anterior ocular inflammation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02793817
Study type Interventional
Source Kala Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 3
Start date June 2016
Completion date March 2017